No Data
No Data
Strong Buy Rating for Valneva as Ixchiq Vaccine Shows Significant Market Potential
Valneva Secures Multi-Million Grant for Vaccine Access
CEPI Expands Partnership With Valneva With a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine
Kepler Capital Keeps Their Buy Rating on Valneva (0OB3)
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
On Wednesday, Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15.
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.
No Data
1522357560466 : news halt?
TrytosaveabitOP 1522357560466: No! Just no trades in PM yet.